EndoVascular Aortic Dissection Early vs Delayed (NCT07143071) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
EndoVascular Aortic Dissection Early vs Delayed
China4,068 participantsStarted 2025-07-01
Plain-language summary
This is a prospective, multicenter, non-inferior, parallel-controlled observational study. This study aims to compare clinical outcomes of endovascular treatment for acute high-risk type B aortic dissection in the acute phase versus the subacute phase. No interventions will be imposed on the patients' standard treatment. Patients with acute high-risk type B aortic dissection will be grouped based on the actual timing of their treatment.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Acute (2-14 days) high-risk type B aortic dissection.
* Completion of thoracoabdominal aortic CTA before enrollment.
* Ability to understand the study objectives and voluntarily participate, with signed informed consent from the patient or their legal representative.
* Willingness and ability to comply with follow-up visits and study protocols.
Exclusion Criteria:
* Acute complicated type B aortic dissection.
* Traumatic dissection or penetrating aortic ulcer.
* Connective tissue diseases (e.g., Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome).
* Pregnancy, women of childbearing potential, or breastfeeding.
* Uncontrolled active infection or active vasculitis.
* Unsuitable access vessels or infection at the access site.
* Endovascular repair requiring ≥2 branch reconstructions.
* Prior aortic surgery (open or endovascular).
* Life expectancy \<2 years.
* Myocardial infarction or cerebrovascular accident within 4 weeks before enrollment.
* Severe gastrointestinal bleeding, major surgery, myocardial infarction, or uncorrected coagulation dysfunction within 6 weeks before enrollment.
* Other conditions deemed by the investigator to compromise the patient's medical interests or unlikely adherence to the study protocol.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.